Blog
Published August 16, 2021
Executive Summary
Recent updates in the National Drug Reimbursement List (NRDL) have increasingly focused on the expansion of oncology products and highlighted the improving market access environment for innovative oncology therapies in China
This effort first came under the spotlight in 2018 as the National Health Security Administration (NHSA) announced the inclusion of 17 novel oncology agents on the NRDL with discounts averaging ~60%. Subsequent NRDL updates saw comparable levels of price discounts and selection of products targeting the most…
Read Now
Scientific Publications
This retrospective patient medical chart study aimed to assess the treatment patterns and real-world practice outcomes of NMIBC patients who were treated with BCG.
Authors
Sam Chang, Kyle Martin, Dan Shaffer, Amy Guo, Nandini Hadker
Journal
ISPOR Meeting; May 2020
View publication…
Read Now
Blog
Published June 2, 2021
Executive Summary
The Medical Fund Bill would increase drug spending up to 4% of the total healthcare spending in Poland
The reimbursement applications can be reviewed as quickly as 180 days, reducing the typical time-to-market of two – three years
The criteria for “innovativeness” that need to be met for inclusion on the list are still not fully fleshed out to date
Only four of the 12 candidates on the list have been approved by the Health Minister to secure reimbursement…
Read Now
Blog
Published September 22, 2020
Executive Summary
Although CAR-Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment
Key barriers for CAR-T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare
New opportunities to overcome these hurdles are being pursued in the form of innovative pricing and contracting strategies to…
Read Now
White Papers
New targeted oncology treatment regimens have changed cancer treatment. This white paper charts that development and analyzes five different approaches, providing an overview of how these paradigms determine strategic choices for commercial success. We observe that:
The oncology treatment landscape has five distinct treatment paradigms.
Competition, routes of administration, and market dynamics differ dramatically for each paradigm.
The approach to commercialization needs to differ for each paradigm to increase uptake and ensure successful market penetration.
Download the White Paper…
Read Now
